About Us

We are a pharmaceutical company fighting challenging disease

Alteron Therapeutics focuses on the clinical development of TDP-43 inhibitors for the treatment of cystic fibrosis and neurodegenerative disorders like Alzheimer’s and ALS.

The ALT drugs:

1) are first-in-class TDP-43 inhibiting drugs

2) block TDP-43 nucleic acid binding

3) can penetrate blood brain barrier

4) have shown efficacy in a disease model.




Expert Staff

Our Partnership